Login / Signup

Noninvasive fetal RHD genotyping of RhD negative pregnant women for targeted anti-D therapy in Australia: A cost-effectiveness analysis.

Louisa G GordonCatherine A HylandJonathan A HyettHelen O'BrienGlenda MillardRobert L FlowerGlenn J Gardener
Published in: Prenatal diagnosis (2018)
Given the vulnerable supply of donor plasma and other health concerns, RHD genotyping is an economically sound option for Australia.
Keyphrases
  • pregnant women
  • genome wide
  • high throughput
  • healthcare
  • public health
  • mental health
  • genetic diversity
  • cancer therapy
  • gene expression
  • risk assessment
  • climate change
  • human health
  • social media
  • single cell
  • cell therapy